|View printer-friendly version|
|August 12, 2005 11:40 a.m.|
|Teva Announces Tentative Approval of Risedronate Sodium Tablets|
Jerusalem, Israel, August 12, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Risedronate Sodium Tablets, 5 mg, 30 mg and 35 mg. Final approval is expected upon the resolution of pending patent litigation.